Anhui Anke BioTech Group (300009) — Strategic Asset Allocation Index
Anhui Anke BioTech Group (300009) has a Strategic Asset Allocation Index of 35.0% as of June 2023. Strategic assets (PP&E of CN¥1.20 Billion plus long-term investments of CN¥-) total CN¥1.20 Billion, measured against net assets of CN¥3.43 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Anhui Anke BioTech Group Strategic Asset Allocation Index (2006–2022)
This chart shows how Anhui Anke BioTech Group's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2022. As of June 2023, the index stands at 35.0%, representing strategic assets of CN¥1.20 Billion against net assets of CN¥3.43 Billion CNY. Explore 300009 operating cash flow to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Anhui Anke BioTech Group (2006–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Anhui Anke BioTech Group from 2006 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 300009 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 34.6% | CN¥1.18 Billion | CN¥1.18 Billion | CN¥- | CN¥3.40 Billion | ▲ +4.2 pp |
| 2021 | 30.4% | CN¥881.34 Million | CN¥881.34 Million | CN¥- | CN¥2.90 Billion | ▲ +4.2 pp |
| 2020 | 26.2% | CN¥766.66 Million | CN¥766.66 Million | CN¥- | CN¥2.93 Billion | ▼ -0.4 pp |
| 2019 | 26.6% | CN¥717.25 Million | CN¥717.25 Million | CN¥- | CN¥2.70 Billion | ▼ -14.1 pp |
| 2018 | 40.6% | CN¥816.92 Million | CN¥616.77 Million | CN¥200.15 Million | CN¥2.01 Billion | ▲ +2.4 pp |
| 2017 | 38.2% | CN¥672.02 Million | CN¥525.34 Million | CN¥146.68 Million | CN¥1.76 Billion | ▲ +0.6 pp |
| 2016 | 37.6% | CN¥536.17 Million | CN¥499.44 Million | CN¥36.74 Million | CN¥1.43 Billion | ▲ +2.7 pp |
| 2015 | 34.9% | CN¥441.63 Million | CN¥441.63 Million | CN¥- | CN¥1.26 Billion | ▼ -10.6 pp |
| 2014 | 45.5% | CN¥351.85 Million | CN¥351.85 Million | CN¥- | CN¥773.47 Million | ▲ +0.7 pp |
| 2013 | 44.8% | CN¥295.92 Million | CN¥295.92 Million | CN¥- | CN¥660.60 Million | ▲ +0.5 pp |
| 2012 | 44.2% | CN¥256.66 Million | CN¥256.66 Million | CN¥- | CN¥580.03 Million | ▲ +11.1 pp |
| 2011 | 33.2% | CN¥180.44 Million | CN¥180.44 Million | CN¥- | CN¥543.88 Million | ▲ +9.3 pp |
| 2010 | 23.9% | CN¥124.62 Million | CN¥124.62 Million | CN¥- | CN¥522.30 Million | ▲ +0.7 pp |
| 2009 | 23.2% | CN¥114.79 Million | CN¥114.79 Million | CN¥- | CN¥495.41 Million | ▼ -42.3 pp |
| 2008 | 65.5% | CN¥97.32 Million | CN¥97.32 Million | CN¥- | CN¥148.64 Million | ▼ -14.5 pp |
| 2007 | 80.0% | CN¥109.66 Million | CN¥109.66 Million | CN¥- | CN¥137.09 Million | ▼ -10.2 pp |
| 2006 | 90.1% | CN¥109.98 Million | CN¥109.98 Million | CN¥- | CN¥122.00 Million | — |